Kleeberg, U. R., et al. (2004). Final results of the EORTC 18871/DKG 80-1 randomised phase III trial: rIFN-α2b versus rIFN-γ versus ISCADOR M® versus observation after surgery in melanoma patients with either high-risk primary (thickness> 3 mm) or regional lymph node metastasis. European Journal of Cancer, 40(3), 390-402.
Semiglazov, V. F., et al. (2006). Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer research, 26(2B), 1519-1529.
Kienle, G. S., & Kiene, H. (2010). Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integrative cancer therapies, 9(2), 142-157.
Ostermann, T., et al. (2020). A systematic review and meta-analysis on the survival of cancer patients treated with a fermented Viscum album L. extract (iscador): an update of findings. Complementary Medicine Research, 1-12.